FDA Grants Accelerated Approval to J&J Bispecific Drug for Head and Neck Cancer

Johnson & Johnson's bispecific drug has received accelerated approval from the FDA for treating head and neck cancer. This regulatory decision provides a new treatment option for patients battling this specific type of cancer, potentially improving outcomes and expanding therapeutic strategies in oncology.